Digital Contract

@csrf

Back

Survey Questionnaire Form

Doctor’s details

@if(isset(session()->get('doctor')['vCentralCode']))

Doctor Name *

@else

Doctor Name *

@endif

Age *

Gender *

Male Female

Doctor’s Degree *

Specialty *

Predominant type of practice *

Multi-specialty hospital

Clinic/ nursing home

Government hospital/ medical college

Mixed

Questionnaire

What proportion of your patients present with dyslipidemia? *

<20%

20% - 50%

50% - 80%

>80%

What is the Low-density lipoprotein cholesterol (LDL-C) goal you normally target? *

<100mg/dl

<70 mg/dl

<50 mg/dl

≤30 mg/dl

Individualized based on risk assessment

What are the major concerns that you have regarding the long-term use of statins in your patients? *

Increase of the risk of hemorrhagic stroke

Increase of the risk of cognitive impairment

Increase of the risk of new onset diabetes

Development of myopathy

Derangement of liver enzymes

Do not have any concern

What proportion of your patients succeed in lifestyle modifications after the diagnosis of dyslipidemia? *

<20%

20% - 50%

50% - 80%

>80%

Do you think statins have any effect on cognitive function? *

Yes

Uncertain

What percentage of your patients cannot use statins continuously due to adverse effects (such as muscle symptoms, etc.)? *

0% (I have no statin-intolerant patients)

<10%

10-20%

21-30%

31-50%

>50%

Please indicate your target level of LDL cholesterol after initiation of drug therapy in the following patient groups *

A history of any coronary artery disease: The target level of LDL cholesterol should be <	mg/dL
Without a history of coronary artery disease but with a history of diabetes mellitus/chronic kidney disease/ischaemic stroke/peripheral artery disease. The target level of LDL cholesterol should be <	mg/dL
Without a history of the conditions listed above: The target level of LDL cholesterol should be <	mg/dL

Below what LDL cholesterol levels do you have concerns for safety in patients? *

20 mg/dL (0.52 mmol/L)

30 mg/dL (0.78 mmol/L)

40 mg/dL (1.03 mmol/L)

50 mg/dL (1.29 mmol/L)

60 mg/dL (1.55 mmol/L)

70 mg/dL (1.80 mmol/L)

Do you think markedly low LDL cholesterol levels affect the incidence of hemorrhagic stroke? *

Yes

Uncertain

How much does the LDL cholesterol level affect the risk of inducing atherosclerotic cardiovascular diseases? *

Affects the risk significantly

Affects the risk moderately

Uncertain

Affects the risk to a small extent

Does not affect the risk

Do you sometimes use "low HDL cholesterol level" as a risk index of atherosclerotic cardiovascular diseases like atherosclerotic cardiovascular disease (ASCVD), coronary artery diseases, non-cardiogenic cerebral infarction) or a therapeutic efficacy index in your medical practice? *

HDL cholesterol level is not used

HDL cholesterol level is sometimes used as 'a risk index of ASCVD'

HDL cholesterol level is sometimes used as 'a therapeutic efficacy index.'

HDL cholesterol level is sometimes used as both 'a risk index of ASCVD' and 'a therapeutic efficacy index

Concerning familial hypercholesterolemia (FH) which best reflects your practice? *

I know about FH and have patients with FH (which was found by my diagnosis)

I know about FH and have referred patients with suspected FH to some other medical institution/physician.

I do not know about FH.

When you make a diagnosis of familial hypercholesterolemia in an adult patient (15-year-old or older), which of the following do you perform? (More than one item can be selected) *

Palpation of Achilles tendon

X-ray photography of Achilles tendon

Take a family history of hyper-LDL-cholesterolaemia

Take a family history of FH

Do you think patients with familial hypercholesterolemia (FH) have an increased incidence of ischemic stroke? *

Yes

Uncertain

In your observation what is the predominant effect of statins on renal function? *

Slowing the decline of the glomerular filtration rate.

Reducing the rate of kidney function loss.

Preventing renal injury and enhancing renal perfusion.

Reducing proteinuria and kidney function loss

Exhibiting anti-inflammatory, antioxidant, and plaque-stabilizing capacities

Do you think the lowering of LDL cholesterol reduces ASCVD events in patients with chronic kidney disease (CKD)? *

Yes

Uncertain

According to you LDL cholesterol lowering therapy is most effective for patients with which stage of chronic kidney disease (CKD)? *

Stage 1

Stage 2

Stage 3

At all stages of CKD

What do you think is the target LDL cholesterol level for primary prevention of the patients with chronic kidney disease (CKD)? *

< 140 mg/dL (< 3.62 mmol/L)

< 120 mg/dL (< 3.10 mmol/L)

< 100 mg/dL (< 2.6 mmol/L)

< 70 mg/dL (< 1.8 mmol/L)

What is your choice of therapy in high-risk patients along with statins if LDL-C is above target? *

Fibrates

Ezetimibe

PCSK 9i

Bempedoic acid

Do you think the target LDL cholesterol level is different between patients with different CKD stage? *

Yes

Uncertain

Do you think there is a clinical benefit to treat chronic kidney disease (CKD) patients with hypertriglyceridemia? *

Yes

Uncertain

How do you treat chronic kidney disease (CKD) patients with hypertriglyceridemia? *

Use statins

Use fibrates

Use nicotinic acid derivatives

Use n-3 polyunsaturated fatty acid

Manage through lifestyle modification without medications

Which regimen of statin therapy do you prefer to use in patients of dyslipidemia with chronic kidney disease (CKD)? *

Low intensity statin therapy

Moderate intensity statin therapy

High intensity statin therapy

Do you try to compensate with additional non statin agents when statins are used at a lower dose? *

Yes

Do you use any additional biomarkers for cardiovascular diseases (CVD) risk stratification? *

Yes